Abstracts

1045 – Acceptability of a Dolutegravir Dispersible Tablet and a Novel Oral Film Formulation in Neonates

Background Current antiretroviral (ARV) syrups used for HIV prevention and early treatment in neonates are from older, more toxic drug classes. Dolutegravir (DTG) is one of the preferred ARVs for children, but there is no pediatric formulation specifically tailored for use in neonates. We report on the mothers’ acceptability of DTG dispersible tablets (DTG-DT) and…

1259 – Substance Use and Treatment Among Reproductive-Age Women With/Without HIV in the Southern US

Background Women with HIV (WWH) who engage in substance use (SU) have poor HIV-related outcomes. Additionally, mortality associated with overdose has recently increased among pregnant and postpartum persons. We characterized SU and treatment among cisgender, reproductive age WWH and women without HIV (WWoH) enrolled in the Study of Treatment And Reproductive Outcomes (STAR). Methods Baseline…

998 – Prematurity and Low Birth Weight in Children Born to Mothers Living With HIV in Spain

Background Children uninfected but exposed to HIV intra-utero (CHEU) are at higher risk of prematurity and low birth weight (LBW), factors associated with long-term growth impairment. Data is scarce regarding the effects of integrase inhibitor regimens during pregnancy in non-limited resource settings. Methods Descriptive retrospective study of mother-child pairs from 62 Spanish hospitals in the…

1041 – Immune Correlates of Viral Rebound During Broadly Neutralizing Antibody Treatment in Children

Background Determining immunologic correlates that may be associated with virologic suppression while on alternate or curative HIV therapy is a priority for children. We longitudinally investigated immune responses among participants in the Tatelo Study with and without virologic failure during 6 months of dual bNAb-treatment after ART interruption. Methods Using multiparametric spectral flow cytometry we…

986 – Depression, Sleep, and Anxiety Among Pregnant and Postpartum Women Using Dolutegravir and Efavirenz

Background Dolutegravir (DTG) and Efavirenz (EFV) have been associated with neuropsychiatric symptoms, which may impact adherence to antiretroviral therapy (ART) in pregnant and postpartum people living with HIV. However, their impact on postpartum mental health remains insufficiently understood. We compared depression, sleep disturbances and anxiety between DTG and EFV treatment in pregnant and postpartum people…

1036 – Association Between HIV-Specific Antibodies and HIV Reservoir Markers in Early-Treated Children

Background Children who initiated early antiretroviral therapy (ART) are potential candidates for ART-free virological control. Low antibody responses to Env (gp160, gp41) or Gag (p24) HIV proteins have been reported associated with low HIV reservoir size. This study aimed to characterize HIV protein-specific antibody and HIV reservoir size in children who initiated early ART and…

1063 – Psychotic Disorders in Young Adults With Perinatally Acquired HIV: A Multicentre UK Study

Background Single cohort UK data suggests an increased lifetime prevalence of psychosis in young people living with perinatally acquired HIV (YPaHIV) compared to age matched peers in the general population (0.5-1.0%), echoed by US data. This is thought to be due to lifelong exposure to a neurotropic virus, neuroinflammation during brain development, and greater experience…

1008 – Impact of Offering PrEP Choice on HIV Incidence in High-Risk Pregnant Women in Kenya

Background HIV incidence remains a significant concern among pregnant and postpartum women. Offering multiple HIV PrEP options can increase coverage and use, yet the impact of HIV infections averted with implementation of various HIV PrEP options for pregnant/postpartum women is unknown. Methods We developed an equation to project HIV incidence through pregnancy and postpartum between…